TRENDING :  Market Movers  |  Top 50   AAPL (-0.23%)    FB (-0.89%)    KO (-0.77%)    AMZN (-0.91%)    UGAZ (4.96%)    VXXB (-3.5%)    MGM (3.07%)    MDB (1.02%)    KRE (2.17%)    AMD (2.38%)    ABMD (1.19%)    AA (0.25%)    IVC (12.08%)    HTGM (2.18%)    GOOS (-2.76%)    GH (4.51%)    GEVO (1.66%)    FUV (-31.27%)    FCEL (12.84%)    DIS (1.75%)    DGAZ (-4.98%)    CRON (2.26%)    CRM (-0.27%)    CGC (3.13%)    CAT (2.7%)

 CLVS - Clovis Oncology

$25.49 [0.02][0.08%]

Next Earnings

2/26/2019

BMO

Recommend
Trade Idea »



ANALYST RATINGS

Quarterly Rating Chart
Rating

2


1=Strong Buy, 2=Buy, 3=Hold, 4=Underperform, 5=Sell
Price Targets
High $40.00
Low $40.00
Average $40.00
Current $25.49

CompanyAnalyst NamePT ActionActionRatingTargetDate
H.C. WainwrightAnnouncesInitiates Coverage OnBuy$40.0002/13/19
*Last 90 days

OPEN RECOMMENDATIONS

No recommendations found.
Options
Service NameTrader NameStrategy% ReturnIssue Date
Best Trading IdeasBest Trading IdeasBuy Calls0.00 %01/21/19View


This list is limited to recommendations made in last 7 days only. Subscribe to a service to see all their recommendations.

TRADERS TRACKING $CLVS

TRENDING ARTICLES



Notable Friday Option Activity: CARA, CLVS, TCX

02/08/19
Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Cara Therapeutics Inc Symbol CARA where a total volume of 2 212 contracts has been traded thus far today a contract volume which is representative of approximately 221

Clovis' Rubraca Gets Nod as Maintenance Therapy in Europe

01/28/19
Clovis Oncology Inc CLVS announced that the European Commission EC has granted approval to a label expansion of its PARP inhibitor Rubraca rucaparib which will expand the drug s eligible patient population The drug is now approved as a maintenance treatment in recurrent ovarian

Analysts Anticipate IYH Will Reach $216

01/25/19
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For the